LEADER 05649nam 2200649Ia 450 001 9910163021603321 005 20200520144314.0 010 $a1-283-15352-1 010 $a9786613153524 010 $a3-8055-9195-0 035 $a(CKB)2610000000006643 035 $a(EBL)3016399 035 $a(SSID)ssj0000543418 035 $a(PQKBManifestationID)12207063 035 $a(PQKBTitleCode)TC0000543418 035 $a(PQKBWorkID)10519109 035 $a(PQKB)11661469 035 $a(MiAaPQ)EBC3016399 035 $a(OCoLC)655261985 035 $a(SZ-BaSKA)249897 035 $a(PPN)146226895 035 $a(EXLCZ)992610000000006643 100 $a20100127d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCurrent indications for growth hormone therapy /$fvolume editor, Peter C. Hindmarsh 205 $a2nd, rev. ed. 210 $aBasel ;$aNew York $cKarger$d2010 215 $a1 online resource (136 p.) 225 0 $aEndocrine development,$x1421-7082 ;$vv. 18 300 $aDescription based upon print version of record. 311 $a3-8055-9194-2 320 $aIncludes bibliographical references and indexes. 327 $a""Cover""; ""Contents""; ""Preface""; ""Chapter 1: Clinical Trials: Planning and Analysis""; ""Abstract""; ""Introduction""; ""Statistical Structure for Planning of Trials""; ""Randomization""; ""Outcomes in Studies of Growth Hormone Therapy""; ""Longitudinal Measurements""; ""Multiple Outcomes""; ""Issues Related to Trial Design""; ""Interpretation of Negative Trials""; ""Non-Inferiority Trials""; ""Conclusion""; ""References""; ""Chapter 2: The Evidence Base for Growth Hormone Effectiveness in Children""; ""Abstract""; ""Evidence Is Not Truth a??? How Do We Know What We Know?"" 327 $a""GH Therapy a??? How Do We Define Benefit and What Is the Evidence?""""Height Screening/Monitoring""; ""Bone Age and Predicted Height as a Surrogate""; ""Where Does Evidence-Based Child Health Fit in Endocrinology""; ""Conclusions""; ""References""; ""Chaper 3: Safety of Recombinant Human GrowthHormone""; ""Abstract""; ""Short-Term Safety Issues""; ""Longer Term Safety Considerations""; ""Tumour Risk and Growth Hormone Treatment""; ""Conclusion""; ""References""; ""Chapter 4: Diagnosis of Growth Hormone Deficiency""; ""Abstract""; ""Introduction""; ""Clinical Examination and Auxology"" 327 $a""Measuring GH Secretion""""Using Downstream Targets of GH Action a??? IGF-1 and IGFBP-3""; ""Neuroradiology""; ""Conclusions""; ""References""; ""Chapter 5: Biological Determinants of Responsiveness to Growth Hormone: Pharmacogenomics and Personalized Medicine""; ""Abstract""; ""Introduction""; ""Pharmacogenomics of Growth""; ""GH Insensitivity (GHI)""; ""GH Receptor""; ""Altered GHR Signaling""; ""Growth Responsiveness to GH Therapy, the Impact of the Growth Plate""; ""Conclusions""; ""References"" 327 $a""Chapter 6: Clinical Considerations in Using Growth Hormone Therapy in Growth Hormone Deficiency""""Abstract""; ""Introduction""; ""Growth Hormone Therapy""; ""Conclusions""; ""References""; ""Chapter 7: Current Indications for Growth Hormone Therapy for Children and Adolescents""; ""Abstract""; ""Introduction""; ""Growth Hormone Deficiency (GHD)""; ""Chronic Renal Insufficiency (CRI), also Known as Chronic Kidney Disease (CKD)""; ""Turner Syndrome (TS)""; ""Children Born Small-for-Gestational Age (SGA), Who Fail to Catch Up to the Normal Growth Channels""; ""Prader-Willi Syndrome (PWS)"" 327 $a""Idiopathic Short Stature (ISS)""""SHOX Gene Haploinsufficiency (SHOX)""; ""Noonan Syndrome (NS)""; ""Conclusions""; ""References""; ""Chapter 8: GH Use in the Transition of Adolescence to Adulthood""; ""Abstract""; ""Introduction""; ""Who, When and How Do We Retest for GH Deficiency during Transition?""; ""Efficacy Data""; ""Dose""; ""Follow-Up""; ""Conclusions""; ""References""; ""Author Index""; ""Subject Index"" 330 $aGrowth hormone (GH) has been used therapeutically for over 50 years. Since the development of a nearly unlimited supply of recombinant human GH in the mid-1980s, children with less severe GH deficiency can also profit from GH replacement therapy. Careful and accurate diagnosis and specific dosing, both essential to ensure normal height development, require the clinician to understand the finer points of clinical trials, to acquire quality evidence and assess the benefits of therapeutic intervention. Furthermore, genetic and environmental factors influencing GH sensitivity and responsiveness need to be taken into account. In this second edition all these aspects are covered in depth. Clinical examination, detailed auxological measurements, bone age assessment, molecular analysis and neuro-radiological evaluation as well as an adaptive strategy of dosing focusing on a patient?s individual responsiveness are discussed in detail. This volume of Endocrine Development is essential reading for pediatric endocrinologists, pediatricians and clinical nurse specialists involved in GH therapy. 410 0$aEndocrine Development 606 $aSomatotropin$xTherapeutic use 606 $aSomatotropin$vPopular works 615 0$aSomatotropin$xTherapeutic use. 615 0$aSomatotropin 676 $a615/.363 686 $a610$2sdnb 701 $aHindmarsh$b P. C$g(Peter C.)$0960349 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910163021603321 996 $aCurrent indications for growth hormone therapy$92788817 997 $aUNINA